Abstract
The debate concerning use of fetal tissue in a clinical setting is relevant to the treatment of diabetes; the ban on clinical use of fetal tissue remains in force. Specifically, this issue raises questions about what has been and what can be done in the use of HFP tissue for treatment of the IDDM patient. The possibility of using such tissue was first raised by Lazarow et al. in the 1973 Banting Lecture (1). Since that time there has been much progress in our understanding of the allograft response and in studies of the growth and differentiation of the HFP. In this report, we review developments in this area and consider their implications in the current political climate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
